Tramadol for osteoarthritis
- 19 July 2006
- journal article
- review article
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 3,p. CD005522
- https://doi.org/10.1002/14651858.cd005522.pub2
Abstract
Background Tramadol is increasingly used for the treatment of osteoarthritis because, in contrast to nonsteroidal anti-inflammatory drugs (NSAIDs), tramadol does not produce gastrointestinal bleeding or renal problems, and does not affect articular cartilage. Objectives We sought to determine the analgesic effectiveness, the effect on physical function, the duration of benefit and the safety of oral tramadol in people with osteoarthritis. Search strategy We searched the Cochrane Central Register of Controlled Trials ( CENTRAL), MEDLINE, EMBASE and LILACS databases up to August 2005. Selection criteria We included randomized controlled trials (RCTs) that evaluated the effect of tramadol or tramadol plus paracetamol on pain levels and/or physical function in people with osteoarthritis. No language restriction was applied. Data collection and analysis We analyzed separately placebo-controlled and active-controlled studies. We used fixed-effect models for the meta-analyses as the results across studies were similar. Main results We included eleven RCTs with a total of 1019 participants who received tramadol or tramadol/paracetamol and 920 participants who received placebo or active-control. The placebo-controlled studies indicated that participants who received tramadol had less pain (-8.5 units on a 0 to 100 scale; 95% confidence interval (CI) -12.0 to -5.0) than patients who received placebo. This represents a 12% relative decrease in pain intensity from baseline. Participants who received tramadol had a 37% increase (95% CI 1.2 to 1.5) in the likelihood of reporting moderate improvement (number needed to treat to benefit = 6; 95% CI 4 to 9). Participants who received tramadol had 2.27 times the risk of developing minor adverse events and 2.6 times the risk of developing major adverse events, compared to participants who received placebo. Of every eight people who receive tramadol or tramadol/paracetamol, one will stop taking the medication because of adverse events, number needed to treat to harm (NNTH)= 8 ( 95% CI 7 to 12) for major adverse events. No conclusion could be drawn on how tramadol or tramadol/paracetamol compared with available pharmacological treatments because of the limited number of studies that evaluated such therapies. Authors' conclusions Tramadol or tramadol/paracetamol decreases pain intensity, produces symptom relief and improves function, but these benefits are small. Adverse events, although reversible and not life threatening, often cause participants to stop taking the medication and could limit tramadol or tramadol plus paracetamol usefulness.Keywords
This publication has 46 references indexed in Scilit:
- Acetaminophen for osteoarthritisCochrane Database of Systematic Reviews, 2006
- Pathogenesis and management of pain in osteoarthritisThe Lancet, 2005
- Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the kneeJournal of Pain and Symptom Management, 2004
- Osteoarthritis: symptoms, signs and source of painInflammopharmacology, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- What decline in pain intensity is meaningful to patients with acute pain?Pain, 2003
- Tramadol/ParacetamolDrugs, 2003
- Celecoxib for rheumatoid arthritisPublished by Wiley ,2002
- Update of ACR Guidelines for Osteoarthritis: Role of the CoxibsJournal of Pain and Symptom Management, 2002
- Tramadol in Musculoskeletal Pain – A SurveyClinical Rheumatology, 2002